MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 111 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
In Reply:
Ivo A. Olivotto, Pauline T. Truong, Vanessa Bernstein, James K. Kelly
2005· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · insufficient_payloadconsensus · none
1
citations
afffundno abstractunlabeled
Reply to C.M. Booth et al
Pamela J. Goodwin, Karla V. Ballman, Eric J. Small, M. Levine, Stephen A. Cannistra
2013· letter· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Neurocognitive testing to predict ICANS post-CAR T.
William Wesson, Lauren J Scott, Nahid Suleman, Shaun DeJarnette, Al‐Ola Abdallah, Forat Lutfi +10 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
A phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian cancer (EOC): Updated survival analysis from OVATION-2 trial.
Premal H. Thaker, Debra L. Richardson, Andrea R. Hagemann, Melanie Bergman, Bhavana Pothuri, Stephen DePasquale +14 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Concordance analysis between tumor tissue HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH) and a translational analysis of plasma ctDNA in patients (pts) with biliary tract cancer (BTC): An exploratory analysis from the phase 2 HERIZON-BTC-01 trial.
James J. Harding, Jin Won Kim, Do‐Youn Oh, Heung-Moon Chang, Emerson Yu-sheng Chen, Dong Uk Kim +11 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
PSMA-targeted imaging with <sup>18</sup>F-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Frédéric Pouliot, Michael A. Gorin, Steven P. Rowe, Lawrence Saperstein, David Josephson, Peter R. Carroll +12 more
2021· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Julie Lemieux, Paul E. Goss, Wendy R. Parulekar, James N. Ingle, Kathleen I. Pritchard, Nicholas J. Robert +7 more
2016· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About